Amylyx Pharmaceuticals, Inc.
AMLX
$14.05
$0.261.89%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -33.00M | -34.39M | -41.44M | -35.91M | -37.55M |
| Total Depreciation and Amortization | 108.00K | 120.00K | 141.00K | 156.00K | 160.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.90M | 5.83M | 6.09M | 5.13M | 5.08M |
| Change in Net Operating Assets | 92.00K | -1.94M | 9.96M | -9.20M | -26.70M |
| Cash from Operations | -27.90M | -30.37M | -25.25M | -39.82M | -59.01M |
| Capital Expenditure | -86.00K | -24.00K | -17.00K | -11.00K | -36.22M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 29.55M | 5.26M | 23.01M | -43.65M | 101.20M |
| Cash from Investing | 29.47M | 5.24M | 22.99M | -43.66M | 64.98M |
| Total Debt Issued | -375.00K | 191.11M | 0.00 | 65.58M | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 376.00K | 2.66M | 72.00K | 970.00K | 148.00K |
| Repurchase of Common Stock | -209.00K | -2.16M | -103.00K | -885.00K | -38.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -208.00K | 191.61M | -31.00K | 65.66M | 110.00K |
| Foreign Exchange rate Adjustments | 118.00K | 151.00K | 608.00K | 197.00K | -525.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.48M | 166.63M | -1.68M | -17.62M | 5.56M |